التفاصيل البيبلوغرافية
| العنوان: |
High Arterial Blood Pressure during Anti-angiogenic Therapy: Friend or Foe? |
| المؤلفون: |
Scartozzi, Mario, Giampieri, Riccardo, Bittoni, Alessandro, Galizia, Eva, Berardi, Rossana, Cascinu, Stefano |
| المصدر: |
European Journal of Clinical & Medical Oncology; 2009, Vol. 1 Issue 1, p1-10, 10p, 5 Diagrams, 4 Charts |
| مصطلحات موضوعية: |
VASCULAR endothelial growth factors, NEOVASCULARIZATION inhibitors, BLOOD pressure, CARDIOVASCULAR disease prevention, HYPERTENSION, NEOVASCULARIZATION, ANTINEOPLASTIC agents, BLOOD-vessel development, GROWTH factors, GENE therapy |
| مستخلص: |
Arterial hypertension is a common side-effect for patients treated with inhibitors of vascular endothelial growth factor (VEGF) signaling. Recent findings indicated a possible role for hypertension as a biomarker of efficacy for angiogenesis inhibitors. An increase in arterial blood pressure during treatment could then predict a better outcome for patients. Globally, these observations seem to suggest that correct management and a full knowledge of the wide spectrum of clinical and molecular manifestations underlying anti-angiogenic therapy-induced hypertension may represent a crucial step in the clinical management of patients treated with this new class of agents. However, the molecular mechanisms underlying the development of hypertension during anti-angiogenic treatment are still not fully understood, with research in this area representing a field of major scientific interest worldwide. In the present literature review, we focused on both the putative molecular basis responsible for arterial hypertension and the relationship between this biological phenomenon and clinical outcome for different anti-angiogenic treatments. The promising association between hypertension induced by VEGF inhibitors and clinical outcome remains to be established in future prospective studies on larger series of patients. Further studies analyzing this correlation should focus on blood pressure increase during treatment, not only as a possible selection tool but, even more importantly, as a molecular key for a better understanding of molecular changes deriving from anti-angiogenic therapies. [ABSTRACT FROM AUTHOR] |
|
Copyright of European Journal of Clinical & Medical Oncology is the property of San Lucas Medical and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
